Potential applications of PET imaging in developing novel cancer therapies

Journal of Nuclear Medicine

Volumn 40, Issue 6, 1999, Pages 995-1002

  Hustinx, Roland ^b   Eck, Stephen L ^b   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Gene therapy; PET

Indexed keywords

CANCER GENETICS; CANCER THERAPY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL HYPOXIA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HAPLORHINI; HUMANS; ISOTOPE LABELING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED;

EID: 0033067830     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Alavi JB, Eck SL. Gene therapy for malignant gliomas. Hematol Oncol Clin North Am. 1998;12:617-629.
2. Boxhorn HKE, Eck SL. Gene therapy for breast cancer. Hematol Oncol Clin North Am. 1998;12:665-675.
3. Dubinett SM, Miller PW, Sharma S, Batra RK. Gene therapy for lung cancer. Hematol Oncol Clin North Am. 1998;12:569-594.
4. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am. 1998;12:595-615.
5. Malkowicz SB, Johnson JO. Gene therapy for prostate cancer. Hematol Oncol Clin North Am. 1998;12:649-664.
6. Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol. 1998;16:2548-2556.
7. Matthews T, Boehme R. Antiviral activity and mechanism of action of anciclovir. Rev Infect Dis. 1988;10:5490-5494.
8. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3: 1354-1361.
9. Yang L, Chiang Y, Lenz HJ, et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther. 1998;9:719-728.
10. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
11. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther. 1990;1:125-134.
12. Eck SL, Alavi JB, Alavi A, et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther. 1996;7:1465-1482.
13. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
14. 18F)fluoro-3-hydroxy-2-propoxy)methyl)guanine. J Labelled Compd Radiopharm. 1995;37:193-195.
15. 18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol. 1996;23:787-792.
16. Barrio JR, Namavari M, Satyamurthy N, et al. 8-(F-18)fluoroacyclovir: an in-vivo probe for gene expression with PET [abstract]. J Nucl Med. 1996;37:193P-194P.
17. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res. 1995;55:6126-6132.
18. Morin KW, Knaus EE, Wiebe LI. Non-invasive scintigraphic monitoring of gene expression in a HS V-1 thymidine kinase gene therapy model. Nucl Med Commun. 1997;18:599-605.
19. Germann C, Shields AF, Grierson JR, Morr I, Haberkorn U. 5-Fluoro-1-(2′-deoxy-2′-fluoro-beta-D-ribofuranosyl) uracil trapping in Morris hepatoma cells expressing the herpes simplex virus thymidine kinase gene. J Nucl Med. 1998;39:1418-1423.
20. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 1996;56:4087-4095.
21. Tjuvajev JG, Avril N, Oku T, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998;58: 4333-4341.
22. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557-1562.
23. Barrio JR, Namavari M, Srinivasan A, et al. Carbon-8 radiofluorination of purines: a general approach to probe design for gene therapy in humans. J Labelled Compd Radiopharm. 1997;40:348.
24. 18F)fluoro-1-hydroxy-2-propoxy)methyl)guanine. Bioorg Med Chem. 1997;7:1879-1882.
25. 18F)fluoro-1-hydroxy-2-propoxy)methyl)guanine: radiopharmaceuticals for gene therapy. J Labelled Compd Radiopharm. 1997;40:20-22.
26. Haberkorn U, Altmann A, Morr I, et al. Monitoring gene therapy with herpes simplex virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med. 1997;38:287-294.
27. Haberkorn U, Khazaie K, Morr I, Altmann A, Muller M, van Kaick G. Ganciclovir uptake in human mammary carcinoma cells expressing herpes simplex virus thymidine kinase. Nucl Med Biol. 1998;25:367-373.
28. Gambhir SS, Barrio JR, Wu L, et al. Imaging of adenoviral-directed herpes simplex virus type I thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med. 1998;39:2003-2011.
29. Green LA, Gambhir SS, Barrio JR, et al. Tracer kinetic modeling of 8-(F-18)-fluoroganciclovir PET data: a new tracer for measuring reporter gene expression [abstract], J Nucl Med. 1998;39:10P.
30. Bading JR, Alauddin MM, Fissekis JH, Kirkman E, Raman RK, Conti PS. Pnarmacokinetics of F-18 fluorohydroxy-propoxymethylguanine (FHPG) in primates [abstract]. J Nucl Med. 1997;38:43P.
31. Shiue CY. Shiue GG, McDonald D, Eck S, Alavi AA. Simplified one-pot synthesis of 9-((3-(F-18)fluoro-1-hydroxy-2-propoxy)methyl)guanine ((F-18)FHPG,2) for gene therapy [abstract]. J Nucl Med. 1998;39:231P.
32. Karp JS, Freifelder R, Geagan MJ, et al. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner. J Nucl Med. 1997;38:636-643.
33. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol. 1998;25:175-180.
34. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992;36:2747-2757.
35. Smee DF, Boehme R, Chernow M, Binko BP, Matthews TR. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol. 1985;34:1049-1056.
36. Gambhir SS, Barrio JR, Bauer E, et al. Radiolabeled penciclovir: a new reporter probe with improved imaging properties over ganciclovir for imaging herpes-simplex virus type 1 thymidine kinase reporter gene expression [abstract]. J Nucl Med. 1998;39:53P.
37. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23: 17-22.
38. Haberkorn U, Belleman ME, Gerlach L, et al. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther. 1998;5:880-887.
39. Haberkorn U, Altmann A, Mon I, Germann C, Oberdorfer F, van Kaick G. Multitracer studies during gene therapy of hepatoma cells with herpes simplex virus thymidine kinase and ganciclovir. J Nucl Med. 1997;38:1048-1054.
40. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 1984;10:695-712.
41. Adams GE, Hypoxia-mediated drugs for radiation and chemotherapy. Cancer. 1981;48:696-707.
42. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45-50.
43. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941-943.
44. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831-838.
45. 2 tension measurements. Cancer Res. 1991;51:6098-6102.
46. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-1515.
47. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer. 1998;79:365-369.
48. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994;29:427-431.
49. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1994;30:635-642.
50. Nozue M, Lee I, Yuan F, et al. Interlaboratory variation in oxygen tension measurement by Eppendorf "histograph" and comparison with hypoxic marker. J Surg Oncol. 1997;66:30-38.
51. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys. 1997;37:897-905.
52. Bremner JC, Stratford IJ, Bowler J, Adams GE. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990;61:717-721.
53. Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res. 1990;124:S38-S43.
54. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer. 1984;54:2441-2449.
55. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
56. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
57. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194: 795-800.
58. Valk P, Mathis C, Prados M, Gilbert J, Budinger T. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33: 2133-2137.
59. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography, Int J Radiat Oncol Biol Phys. 1995;33:391-398.
60. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys. 1995;22:1127-1139.
61. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med. 1996;23:1378-1383.
62. 18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol. 1997;24:755-760.
63. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res. 1996;56:405-411.
64. Evans SM, Koch CJ, Laughlin KM, Jenkins WT, Van Winkle T, Wilson DF. Tamoxifen induces hypoxia in MCF-7 xenografts. Cancer Res. 1997;57:5155-5161.
65. Laughlin KM, Evans SM, Jenkins WT, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 1996;277:1049-1057.
66. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 1995;72:875-882.
67. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993;53:5721-5726.
68. Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med. 1997;38:1130-1134.
69. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
70. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Evaluation of copper-62 ATSM in patients with lung cancer as a hypoxic tissue tracer [abstract]. J Nucl Med. 1998;39:53P.
71. Fujibayashi Y, Yoshimi E, Waki A, Takahashi N, Yonekura Y. Cu-ATSM, a new tumor agent predicting ability for bioreductive drug activation [abstract]. J Nucl Med. 1998;39:90P.
72. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788-792.
73. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of Cu-64-ATSM in vitro and in vivo in a hypoxic model. J Nucl Med. 1999;40:177-183.